These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

734 related items for PubMed ID: 25863806

  • 1. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
    Sai E, Shimada K, Miyauchi K, Masaki Y, Kojima T, Miyazaki T, Kurata T, Ogita M, Tsuboi S, Yoshihara T, Miyazaki T, Ohsaka A, Daida H.
    Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806
    [Abstract] [Full Text] [Related]

  • 2. Impact of chronic kidney disease on patients with unprotected left main coronary artery disease treated with coronary artery bypass grafting or drug-eluting stents.
    Pan Y, Qiu Q, Chen F, Li X, Yu X, Luo Y, Li Q, He J, Gao Y, Zhang X, Ren X.
    Coron Artery Dis; 2016 Nov; 27(7):535-42. PubMed ID: 27269882
    [Abstract] [Full Text] [Related]

  • 3. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.
    Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.
    JACC Cardiovasc Interv; 2016 Jan 11; 9(1):28-38. PubMed ID: 26762908
    [Abstract] [Full Text] [Related]

  • 4. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
    Miao Y, Yu-Jie Z, Zhi-Jian W, Dong-Mei S, Yu-Yang L, Ying-Xin Z, Fei G, Shi-Wei Y, De-An J.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):361-7. PubMed ID: 22419375
    [Abstract] [Full Text] [Related]

  • 5. Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).
    Girasis C, Farooq V, Diletti R, Muramatsu T, Bourantas CV, Onuma Y, Holmes DR, Feldman TE, Morel MA, van Es GA, Dawkins KD, Morice MC, Serruys PW.
    JACC Cardiovasc Interv; 2013 Dec 01; 6(12):1250-60. PubMed ID: 24355115
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M, Kimura T, Morimoto T, Hayashi Y, Shiode N, Nishikawa H, Nakao K, Shirota K, Kawai K, Hiasa Y, Kadota K, Nozaki Y, Isshiki T, Sone T, Mitsudo K, j-Cypher Registry Investigators.
    JACC Cardiovasc Interv; 2013 Jul 01; 6(7):654-63. PubMed ID: 23866178
    [Abstract] [Full Text] [Related]

  • 8. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry.
    Lee JM, Kang J, Lee E, Hwang D, Rhee TM, Park J, Kim HL, Lee SE, Han JK, Yang HM, Park KW, Na SH, Kang HJ, Koo BK, Kim HS.
    JACC Cardiovasc Interv; 2016 Oct 24; 9(20):2097-2109. PubMed ID: 27692820
    [Abstract] [Full Text] [Related]

  • 9. Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention.
    Grandjean-Thomsen NL, Marley P, Shadbolt B, Farshid A.
    Nephron; 2017 Oct 24; 137(1):23-28. PubMed ID: 28478459
    [Abstract] [Full Text] [Related]

  • 10. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.
    Ishii H, Toriyama T, Aoyama T, Takahashi H, Amano T, Hayashi M, Tanaka M, Kawamura Y, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T.
    Circ Cardiovasc Interv; 2009 Dec 24; 2(6):513-8. PubMed ID: 20031768
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years.
    Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Valstar G, van Geuns RJ, van der Giessen W, van Domburg R, Serruys P, Interventional Cardiologists of Thoraxcenter.
    Catheter Cardiovasc Interv; 2012 Jul 01; 80(1):18-26. PubMed ID: 21735520
    [Abstract] [Full Text] [Related]

  • 13. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
    Sardi GL, Loh JP, Torguson R, Laynez-Carnicero A, Kitabata H, Xue Z, Satler LF, Pichard AD, Waksman R.
    Cardiovasc Revasc Med; 2014 Mar 01; 15(2):86-91. PubMed ID: 24684759
    [Abstract] [Full Text] [Related]

  • 14. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
    Rothman MT, Jain AK, E-Five Registry Investigators.
    Catheter Cardiovasc Interv; 2012 Nov 15; 80(6):885-92. PubMed ID: 22517785
    [Abstract] [Full Text] [Related]

  • 15. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X, Chen F, He J, Gao Y, Wu C, Luo Y, Zhang X, Zhang Y, Ren X, Lv S.
    Coron Artery Dis; 2013 May 15; 24(3):217-23. PubMed ID: 23425771
    [Abstract] [Full Text] [Related]

  • 16. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 15; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 17. The burden of major adverse cardiac events in patients with coronary artery disease.
    Tsai IT, Wang CP, Lu YC, Hung WC, Wu CC, Lu LF, Chung FM, Hsu CC, Lee YJ, Yu TH.
    BMC Cardiovasc Disord; 2017 Jan 04; 17(1):1. PubMed ID: 28052754
    [Abstract] [Full Text] [Related]

  • 18. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A.
    Clin Res Cardiol; 2016 Jul 04; 105(7):575-84. PubMed ID: 26689707
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.
    Catheter Cardiovasc Interv; 2013 Apr 04; 81(5):759-65. PubMed ID: 22488756
    [Abstract] [Full Text] [Related]

  • 20. Association of moderate chronic kidney disease with insufficient improvement of fractional flow reserve after stent implantation.
    Sakoda K, Tanaka N, Hokama Y, Hoshino K, Murata N, Yamashita J, Yamashina A.
    Catheter Cardiovasc Interv; 2016 Aug 04; 88(2):E38-44. PubMed ID: 26489880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.